

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
2 July 2009 (02.07.2009)

PCT

(10) International Publication Number
WO 2009/082347 A1

(51) International Patent Classification:

C07D 307/79 (2006.01) **C07C 311/44** (2006.01)
A61K 31/18 (2006.01) **C07D 209/10** (2006.01)
A61K 31/341 (2006.01) **C07D 213/30** (2006.01)
A61K 31/343 (2006.01) **C07D 213/64** (2006.01)
A61K 31/381 (2006.01) **C07D 233/96** (2006.01)
A61K 31/404 (2006.01) **C07D 271/10** (2006.01)
A61K 31/4155 (2006.01) **C07D 277/32** (2006.01)
A61K 31/4245 (2006.01) **C07D 307/10** (2006.01)
A61K 31/426 (2006.01) **C07D 307/38** (2006.01)
A61K 31/4402 (2006.01) **C07D 333/34** (2006.01)
A61K 31/4418 (2006.01) **C07D 333/76** (2006.01)
A61K 31/505 (2006.01) **C07D 409/04** (2006.01)
A61P 29/00 (2006.01)

R & D Södertälje, S-151 85 Södertälje (SE). **MINIDIS, Alexander** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **NORDVALL, Gunnar** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **SOHN, Daniel** [US/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **VALLIN, Karl S.A** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **VIKLUND, Jenny** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **VON BERG, Stefan** [DE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE).

(74) Agent: **ASTRAZENECA AB**; AstraZeneca Intellectual Property, S-151 85 Södertälje (SE).

(21) International Application Number:

PCT/SE2008/051500

(22) International Filing Date:

18 December 2008 (18.12.2008)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/015,287 20 December 2007 (20.12.2007) US

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BYLUND, Johan** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **EK, Maria E** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **GRAVENFORS, Ylva** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **HOLENZ, Jörg** [DE/SE]; AstraZeneca


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(54) Title: BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY



(57) Abstract: The invention provides compounds of formula (I) wherein $R^1, R^3, L^1, L^2, G^1, G^2$, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of mitochondrial prostaglandin E synthase-1.



WO 2009/082347 A1